What Decision Resources Group Does

Decision Resources Group (DRG), part of Clarivate, is a leading provider of high-value analytics, research, and consulting services to the global pharmaceutical and biotechnology industries. Founded in 1990 and based in Burlington, Massachusetts, the company operates at the intersection of healthcare and business intelligence. Its core function is to empower clients with deep market insights, leveraging proprietary data and expert analysis on drug development, market access, competitive dynamics, and disease-specific trends. DRG synthesizes complex information from clinical trials, real-world evidence, regulatory pathways, and physician surveys to deliver strategic recommendations that guide critical commercial and development decisions.

Why AI Matters at This Scale

For a firm of DRG's size (1,001-5,000 employees), operating in the high-stakes, fast-paced pharmaceutical sector, AI is not a luxury but a competitive imperative. The volume and velocity of healthcare data are exploding, making traditional manual analysis increasingly inadequate. At this mid-market scale, DRG has the resources to fund dedicated data science initiatives and the agility to pilot and integrate new technologies without the paralysis that can affect larger, more bureaucratic enterprises. AI adoption directly addresses client demands for more predictive, real-time insights, moving beyond descriptive reporting to foresight that can shape multi-million-dollar investment decisions. Failure to leverage AI risks ceding ground to more technologically adept competitors and diminishing the value and timeliness of its core offerings.

Concrete AI Opportunities with ROI Framing

1. Automated Insight Synthesis (High ROI): Deploying natural language processing (NLP) and machine learning to automatically analyze and correlate findings from clinical publications, conference abstracts, and market research reports. This reduces analyst drudgery by up to 30%, allowing experts to focus on high-level strategy and client engagement, thereby increasing capacity and accelerating project turnaround times. 2. Predictive Forecasting Models (High ROI): Building proprietary ML models that integrate real-world patient data, pricing information, and competitor intelligence to forecast drug adoption curves and revenue potential. This enhances the accuracy and defensibility of strategic recommendations, allowing DRG to offer premium, predictive advisory services and secure longer-term, higher-value client contracts. 3. Intelligent Client Interaction Tools (Medium ROI): Implementing AI-powered dashboards and chatbots that allow clients to query complex datasets using plain language. This improves client stickiness and satisfaction by providing immediate, self-service access to insights, while generating valuable data on client inquiry patterns to inform service development.

Deployment Risks Specific to This Size Band

At the 1,001-5,000 employee scale, DRG faces distinct implementation risks. Resource Allocation is a primary concern: diverting top analysts to AI training or data curation can impact short-term revenue-generating projects, requiring careful change management. Data Governance becomes critical; with multiple business units and legacy data systems, creating a unified, clean, and AI-ready data lake is a major technical and organizational hurdle. There is also a "Pilot Purgatory" Risk—the company has enough resources to start many small AI projects but may lack the centralized strategy and executive mandate to scale successful pilots into production, leading to wasted investment and fragmented capabilities. Finally, Talent Competition is fierce; attracting and retaining data scientists and AI specialists is challenging and expensive, especially against larger tech and biotech firms in the Boston area.